From Name:
From Email:
To Name:
To Email:

Optional Message:

Durvalumab plus tremelimumab active as neoadjuvant bladder cancer treatment

from Urology Times

Dual immune-checkpoint blockade with the PD-L1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab showed early signs of efficacy in cisplatin-ineligible patients with high-risk localized bladder cancer, according to findings from a phase 1 trial published in Nature Medicine. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063